Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Francisco José Rebollo Laserna"'
Autor:
Juan D. Cañete, Jose Antonio Pinto Tasende, Francisco José Rebollo Laserna, Susana Gómez Castro, Rubén Queiro
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 2, Pp 237-257 (2020)
Abstract Introduction A systematic literature review was conducted with the aim to analyse the impact of comorbidity on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA). Methods A sensitive search strategy of the Medline, E
Externí odkaz:
https://doaj.org/article/6de3f2defd2048b7babab4b592ec5028
Autor:
Lluís Puig, Lourdes Rodríguez Fernández-Freire, Ramón Burgos-Pol, Ismael Gomez, Carmen Peral, Susana Gomez, Francisco José Rebollo Laserna
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 3, Pp 479-496 (2019)
Abstract Introduction Etanercept (ETN), a highly effective biological agent for the treatment of psoriasis (PSO) and psoriatic arthritis (PsA), is widely used in Spain. However, evidence of its economic impact is limited, indicating the need for a sy
Externí odkaz:
https://doaj.org/article/f0a79d22ccaa426c84f56b29812a1ad3
Autor:
Francisco José Rebollo Laserna, Susana Gómez Castro, Carlos Manuel González Fernández, Jordi Gratacós Masmitjá
Publikováno v:
Advances in Therapy. 38:868-884
Therapeutic approaches for psoriatic arthritis (PsA) include non-pharmacologic therapies, symptomatic treatments, tumor necrosis factor inhibitors, interleukin inhibitors, cytotoxic T lymphocyte antigen 4 immunoglobulin, and Janus kinase inhibitors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::272628f1b49e8825610bdc95b4fa239c
https://doi.org/10.1007/s12325-020-01585-7
https://doi.org/10.1007/s12325-020-01585-7
Autor:
José Manuel Carrascosa Carrillo, Eulalia Baselga Torres, Yolanda Gilaberte Calzada, Yanina Nancy Jurgens Martínez, Gastón Roustan Gullón, Juan Ignacio Yanguas Bayona, Susana Gómez Castro, Maria Giovanna Ferrario, Francisco José Rebollo Laserna
Publikováno v:
Dermatology and therapy. 12(5)
As research continues, new drugs will no doubt be added to the current pool of treatments for moderate-to-severe atopic dermatitis (AD). This raises the need for studies to determine prescriber preferences for different pharmacological options and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcc2526d7d701965e426e2d6db626c8d
https://pubmed.ncbi.nlm.nih.gov/35445962
https://pubmed.ncbi.nlm.nih.gov/35445962
Autor:
José Antonio Pinto Tasende, Rubén Queiro, Francisco José Rebollo Laserna, Susana Gómez Castro, Juan D. Cañete
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 2, Pp 237-257 (2020)
Rheumatology and Therapy
Rheumatology and Therapy
Introduction A systematic literature review was conducted with the aim to analyse the impact of comorbidity on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA). Methods A sensitive search strategy of the Medline, Embase and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a68c9d6f644f8e226575ebdfd933d2dc
https://doaj.org/article/6de3f2defd2048b7babab4b592ec5028
https://doaj.org/article/6de3f2defd2048b7babab4b592ec5028
Autor:
Jordi, Gratacós Masmitjà, Carlos M, González Fernández, Susana, Gómez Castro, Francisco José, Rebollo Laserna
Publikováno v:
Advances in therapy. 38(2)
Therapeutic approaches for psoriatic arthritis (PsA) include non-pharmacologic therapies, symptomatic treatments, tumor necrosis factor inhibitors, interleukin inhibitors, cytotoxic T lymphocyte antigen 4 immunoglobulin, and Janus kinase inhibitors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::638271f3a750e2e63d48e57ce0c85d1f
https://pubmed.ncbi.nlm.nih.gov/33331985
https://pubmed.ncbi.nlm.nih.gov/33331985
Autor:
Jose Carlos Peláez Álvarez, Erica Falkenbach, Blanca Piedrafita, Carlos Guijarro Herraiz, María Jesús López Navas, Francisco José Rebollo Laserna, Jose Luis López Estebaranz, Raquel Almodóvar González, Diana Ruiz Genao, Susana Gómez, Juan José Gorgojo-Martínez, Eva De Higes-Martínez, David Palacios, Pedro Zarco Montejo
Publikováno v:
Rheumatology international. 40(6)
The aim of this study was to generate practical recommendations to assist rheumatologists and dermatologists in the management of cardiovascular (CV) comorbidities in patients with moderate-to-severe psoriasis (MS-PSO) and psoriatic arthritis (PsA).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a5c0df2e25dd2b5e1536217144c9274
https://pubmed.ncbi.nlm.nih.gov/32274527
https://pubmed.ncbi.nlm.nih.gov/32274527
Autor:
Ismael Gomez, Lluís Puig, C. Peral, Ramón Burgos-Pol, Lourdes Rodríguez Fernández-Freire, Francisco José Rebollo Laserna, Susana Gómez
Publikováno v:
Dermatology and Therapy
Dermatology and Therapy, Vol 9, Iss 3, Pp 479-496 (2019)
Dermatology and Therapy, Vol 9, Iss 3, Pp 479-496 (2019)
Introduction Etanercept (ETN), a highly effective biological agent for the treatment of psoriasis (PSO) and psoriatic arthritis (PsA), is widely used in Spain. However, evidence of its economic impact is limited, indicating the need for a systematic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15b3d3f87392b634ec60fafd17a1886a
https://hdl.handle.net/10668/13919
https://hdl.handle.net/10668/13919
Autor:
Javier de Castro Carpeño, Agustí Barnadas i Molins, Pere Gascón-Vilaplana, Juan Jesús Cruz Hernández, Carlos Camps Herrero, Ana Maria Casas‑Fernández‑de Tejerina, Antonio Antón Torres, Francisco José Rebollo Laserna, Enrique Aguilar, Rafael López López, Bartomeu Massuti Sureda
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Febrile neutropenia (FN) is one of the most common adverse events associated with myelosuppressive chemotherapy for cancer treatment. The objective of this study was to describe the incidence of hospitalization due to FN in Spanish tertiary care hosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb7fb35d88dc707d936a2904ae66655f
https://hdl.handle.net/20.500.12530/21389
https://hdl.handle.net/20.500.12530/21389
Autor:
Ana Martín-Santiago, MD, Susana Puig, MD PhD, Daniel Arumi, MD PhD, Francisco Jose Rebollo Laserna, MD
Publikováno v:
Current Therapeutic Research, Vol 96, Iss , Pp 100679- (2022)
ABSTRACT: Objective: Evaluate the safety profile and tolerability of topical phosphodiesterase 4 (PDE4) inhibitors versus vehicle as treatment for atopic dermatitis in published studies. Methods: A search was performed in Medline/PubMed, Web of Scien
Externí odkaz:
https://doaj.org/article/c1f70b21120743c3a995cfe90298da6e